These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3308393)

  • 1. The contribution of epidemiology to the study of drugs.
    Porta MS; Hartzema AG
    Drug Intell Clin Pharm; 1987 Sep; 21(9):741-7. PubMed ID: 3308393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
    Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
    Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of pharmacoepidemiology.
    Wertheimer AL; Andrews KB
    Pharm World Sci; 1995 May; 17(3):61-6. PubMed ID: 7550051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding roles of hospital epidemiology: pharmacoepidemiology.
    Burke JP; Tilson HH; Platt R
    Infect Control Hosp Epidemiol; 1989 Jun; 10(6):253-4. PubMed ID: 2661681
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoepidemiology: a new discipline.
    Lawson DH
    Br Med J (Clin Res Ed); 1984 Oct; 289(6450):940-1. PubMed ID: 6435731
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse drug reactions and the elderly.
    Ray WA; Griffin MR; Shorr RI
    Health Aff (Millwood); 1990; 9(3):114-22. PubMed ID: 2227772
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovering adverse drug reactions.
    Lasagna L
    JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug safety, pharmacoepidemiology, and regulatory decision making.
    Nelson RC
    Drug Intell Clin Pharm; 1988 Apr; 22(4):336-44. PubMed ID: 3371198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 11. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can postmarketing surveillance help to effect optimal drug therapy?
    Strom BL; Melmon KL
    JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 15. Postmarketing surveillance: curriculum for the clinical pharmacologist. Part II: Clinical and regulatory considerations.
    Johnson JM; Tanner LA
    J Clin Pharmacol; 1993 Nov; 33(11):1015-22. PubMed ID: 8300884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA Safety and Innovation Act.
    Steinbrook R; Sharfstein JM
    JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication monitoring in the workplace: toward improving our system of epidemiologic intelligence.
    Tilson HH
    J Occup Med; 1990 Apr; 32(4):313-9. PubMed ID: 2335797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.